Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
John Ramunas · REJUVENATION TECHNOLOGIES, INC. · 2024 · $1,858,106 — Abstract Rejuvenation Technologies Inc. (RTI) is taking the next translational step following their recent highly successful proof-of-concept rescue of multiple mouse models that mimic key pathological features of alcoholic hepatitis (AH). AH is an acute form of alcoholic liver disease in which the …
Chyung-Ru Wang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $685,629 — PROJECT SUMMARY Group 1 CD1-restricted T cells are members of the unconventional T cell family that recognize self- and microbial lipid antigens presented by CD1a, CD1b, and CD1c molecules. Group 1 CD1-restricted T cells have been implicated to play critical roles in various autoimmune and infectiou…
Renato Samuel Navarro · STANFORD UNIVERSITY · 2024 · $156,708 — PROJECT SUMMARY Myocardial infarction (MI) is a leading cause of cardiovascular disease and death. After an MI, limited regeneration occurs, and instead, inflammation and scarring cause the affected myocardial tissue to turn fibrotic and thin. This tissue remodeling results in abnormal tissue mechan…
Omar Abdel-Wahab · FRED HUTCHINSON CANCER CENTER · 2024 · $683,443 — SUMMARY Many cancers carry recurrent, change-of-function mutations affecting RNA splicing factors, resulting in sequence-specific changes in RNA splicing that promote disease initiation and progression. These “spliceosomal mutations” are the most common class of mutations in myelodysplastic syndrome…
NAGI G AYAD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2024 · $1,152,811 — PROJECT SUMMARY/ABSTRACT Despite decades of intensive research, there are currently no disease-modifying therapies to treat spinal cord injury (SCI). One major reason for this dire unmet need is the spatiotemporal heterogeneity of the cells that comprise the injury site. Therapeutic molecules (e.g.,…
Kiran Musunuru · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $5,051,652 — PROJECT SUMMARY The potential for the development of novel therapeutic modalities has energized the genome editing field since it first emerged in the 1990s and especially since the demonstration of programmable genome editing with CRISPR-Cas9 by multiple groups in 2012. There has been substantial p…
TREVOR P. CASTOR · APHIOS CORPORATION · 2024 · $504,732 — PROJECT SUMMARY Alzheimer's disease is associated with multiple factors, including but not limited to amyloid plaque formation, tau protein entanglement, enzyme degradation and inflammation. Inflammation is implicated in many aging diseases and in the central nervous system (CNS) is associated with …
Kerry S Campbell · THOMAS JEFFERSON UNIVERSITY · 2024 · $498,670 — Project Summary NK cells are capable of killing virus-infected and cancer cells and, therefore, play an important role in innate host defense. Unlike cytotoxic T lymphocytes (CTL), whose cytolytic activity is induced by productive TCR engagement with cognate pMHC ligands, activation of NK cells is r…
Jiujiu Yu · UNIVERSITY OF NEBRASKA LINCOLN · 2024 · $1 — Obesity is a chronic progressive disease that leads to the development of heart disease, stroke, and type 2 diabetes, which are among the top ten leading causes of death in the United States. The initiation and progression of obesity-related diseases is strongly associated with chronic low-grade inf…
Jayanta Debnath · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $713,896 — PROJECT SUMMARY Glial pathology is increasingly recognized as a key feature in neurodegenerative diseases. However, the exact mechanisms that promotes glial pathology remain unclear. Several studies implicate the autophagy machinery, a highly conserved lysosomal degradation pathway, in maintaining p…
Michelle S Bradbury · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $494,251 — Project Summary: Enormous strides continue to be made in the design of nanoparticles as highly specialized therapeutics for achieving superior outcomes over standard pharmacological agents, the latter often associated with significant toxicity that limits treatment efficacy. While cancer immunothera…
Enrico Tapavicza · CALIFORNIA STATE UNIVERSITY LONG BEACH · 2024 · $147,500 — Project Summary/Abstract There is a dire need in developing new molecular paradigms for pharmacotherapy to address problems of poor drug selectivity, causing side effects, drug resistance, and environmental toxicity. Currently, over 85 % of the drugs in clinical research are discarded due to poor se…
YASUKO IWAKIRI · YALE UNIVERSITY · 2024 · $244,151 — SUMMARY A subset of patients with alcohol-associated liver disease (ALD) develop severe alcoholic hepatitis (AH), carrying a very poor prognosis. Control of inflammation is a key to the treatment of AH. Hepatic lymphatics are highly involved in the regulation of the inflammatory response by dischar…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $664,531 — ABSTRACT With the ability to silence individual genes and to drug the ‘undruggable’, RNA interference (RNAi) therapy has recently shown clinical success by delivering small interfering RNA (siRNA) to the liver for genetic diseases. However, new delivery strategies will be needed to expand the target…
Peng Zhang · NORTHWESTERN UNIVERSITY AT CHICAGO · 2024 · $347,701 — PROJECT SUMMARY/ABSTRACT Radiation therapy (RT) is a key component of standard of care treatments for glioblastoma (GBM), the most common and deadly primary brain malignancy in adults. Beyond the direct cytotoxic effect on tumor itself, RT- elicited anti-tumor immune responses have recently been app…
Brianna Leilani Bourgeois · LSU HEALTH SCIENCES CENTER · 2024 · $47,466 — Abstract The primary purpose of this Ruth L. Kirschstein NRSA F30 application is to provide the groundwork that will prepare the applicant for an academic medical career. Much of the applicant’s career development will come from work in High Priority HIV/AIDS comorbidity-related research, and she wi…
MARSHA A MOSES · BOSTON CHILDREN'S HOSPITAL · 2024 · $248,243 — Project Summary/Abstract Pancreatic cancer (PC) is one of the most lethal forms of cancer in the United States (5-year survival rate below 10%). PC patients are usually diagnosed with a non-resectable disease (80-85%) and have a dismal prognosis with a survival period of only 3-6 months after the…
JOHN M MARIS · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $777,310 — PROJECT SUMMARY This Multiple Principal Investigator (MPI) Project proposal for the Pediatric Immunotherapy Network is focused on high-risk neuroblastoma, a diverse and enigmatic malignancy arising from the developing sympathetic nervous system that remains lethal in 50% of patients despite intensiv…
Pranoti Mandrekar · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $616,844 — ABSTRACT Liver immune cell activation is central to alcohol associated liver disease (ALD) and is poorly understood. The protein homeostasis network/pathways are crucial in safeguarding the cellular proteome from cellular stress. Amongst these, proteostasis mediator HSP90 is widely studied and exte…
Kuo-Ching Mei · STATE UNIVERSITY OF NY,BINGHAMTON · 2024 · $354,807 — Complementary Biotherapeutic Delivery Platforms for Enabling Gene Re-delivery Project Summary Facing the universal challenge of re-delivering Adeno-associated viruses (AAVs), our project endeavors to pioneer delivery-focused solutions in gene therapy. The core obstacle stems from the host immune sys…